Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study

KEY POINTS: Tenapanor is a first-in-class, minimally systemic sodium–hydrogen exchanger 3 inhibitor with a mechanism of action distinct from phosphate binders. Tenapanor alone or with phosphate binders led to 35%–49% of patients achieving serum phosphate ≤4.5 mg/dl over an 18-month period versus 22%...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Arnold L., Chertow, Glenn M., Hernandez, German T., Lynn, Robert I., Tietjen, David P., Rosenbaum, David P., Yang, Yang, Edelstein, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Nephrology 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695649/
https://www.ncbi.nlm.nih.gov/pubmed/37853560
http://dx.doi.org/10.34067/KID.0000000000000280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695649/
https://www.ncbi.nlm.nih.gov/pubmed/37853560
http://dx.doi.org/10.34067/KID.0000000000000280

Ejemplares similares